SLC5A2 and diabetes mellitus: Mean LVEF (31.6% in both groups) and median NT‐proBNP (1470 pg/mL vs. 1717 pg/mL) were similar whether patients were taking an SGLT2 inhibitor or not, whereas a history of diabetes was more common in those taking an SGLT2 inhibitor (79% versus 45%).